Adenoviral Suspension Injection
Adenoviral Suspension Injection - Related Videos
03:20
Large-Scale Production of High-Capacity Adenoviral Vectors
0 Views •
2026
Source: Ehrke-Schulz, E., et al. Cloning and Large-Scale Production of High-Capacity Adenoviral Vectors Based on the Human Adenovirus Type 5. J. Vis. Exp. (2016)This video demonstrates the large-scale amplification of high-capacity adenoviral vectors in suspension-adapted human embryonic kidney cells expressing Cre recombinase for use in gene delivery applications requiring high-titer, helper-free vector preparations.
15:33
Adenoviral Transduction of Naive CD4 T Cells to Study Treg Differentiation
0 Views •
Cited by 7 •
2013
Adenoviral gene transfer into naive CD4 T cells with transgenic expression of the Coxsackie adenovirus receptor enables the molecular analysis of regulatory T cell differentiation in vitro.
04:35
Cesium Chloride-Based Purification of Genome-Containing Adenoviral Vectors
0 Views •
2026
Source: Ehrke-Schulz, E., et al. Cloning and Large-Scale Production of High-Capacity Adenoviral Vectors Based on the Human Adenovirus Type 5. J. Vis. Exp. (2016)This video demonstrates the purification of high-capacity adenoviral vectors using cesium chloride gradient ultracentrifugation, enabling the separation of genome-containing virions for applications in gene delivery, vector characterization, and preclinical therapeutic...
06:04
Performing Subretinal Injections in Rodents to Deliver Retinal Pigment Epithelium Cells in Suspension
0 Views •
Cited by 32 •
2015
Here we present a community accepted protocol in multimedia format for subretinally injecting a bolus of RPE cells in rats and mice. This approach can be used for determining rescue potentials, safety profiles, and survival capacities of grafted RPE cells upon implantation in animal models of retinal degeneration.
16:59
Neo-Islet Formation in Liver of Diabetic Mice by Helper-dependent Adenoviral Vector-Mediated Gene Transfer
0 Views •
Cited by 5 •
2012
We describe hepatic neo-islet formation in STZ (streptozotocin)-induced diabetic mice by gene transfer of Neurogenin3 (Ngn3) and Betacellulin (Btc) using helper-dependent adenoviral vector (HDAd) and the reversal of hyperglycemia. Our method takes advantages of helper-dependent adenoviral vectors with their highly efficient in vivo transduction and the long lasting gene expression.
FAQs
Cell entry follows a receptor-mediated sequence: adenoviral particles first bind receptors on a target cell, then enter through endocytosis. After internalization, the vector releases its DNA, allowing the engineered genetic material to be expressed. This sequence is central to studying whether a treatment reaches the intended cells and produces the desired biological effect.
Some adenoviral designs can replicate selectively in tumor cells, whereas others primarily function as gene-delivery vehicles. Tumor-selective replication is important because it connects vector activity with oncolytic virotherapy, in which viral behavior is investigated as part of the antitumor strategy. Researchers therefore examine replication patterns alongside targeting, safety, and treatment effectiveness.
Beyond delivering genetic material, an adenoviral vector may be designed to stimulate an antitumor immune response. This makes immune-response evaluation an important part of cancer studies, particularly when the intended effect extends beyond direct activity in treated cells. Investigators can assess whether the injection supports an immune-mediated component of the proposed therapeutic approach.
Studies commonly examine several linked outcomes: whether the vector reaches the intended tissue, whether engineered genes are expressed, whether selective replication occurs when designed, and how the immune system responds. Researchers also evaluate safety and treatment effectiveness. Considering these measures together helps distinguish successful delivery from meaningful and acceptable anticancer activity.
A study begins with administering the liquid adenoviral formulation, followed by assessment of its interaction with target cells and tissues. Investigators then examine genetic expression and, when relevant, selective replication or immune activation. Safety and treatment effectiveness are evaluated as additional endpoints, creating a workflow that connects delivery events with cancer-related outcomes.
Researchers use this platform when they need to investigate programmable genetic delivery, tumor-focused viral activity, or immune-based cancer treatment strategies. Its applications include studying oncolytic virotherapy, therapeutic gene delivery, and cancer immunotherapy. The same research approach can therefore address different treatment concepts while emphasizing targeting, biological response, safety, and effectiveness.